Age and Gender Disparities in Cancer Biomarker Expression: Insights from a Population-Based Investigation in Mymensingh District of Bangladesh
DOI:
https://doi.org/10.69728/jst.v10.22Keywords:
cancer biomarkers, cross-section, demographic level, Chemiluminescent microparticle, ELISA, Hepatocellular carcinomaAbstract
Cancer remains a significant global health challenge, necessitating innovative approaches for early detection and targeted therapeutic interventions. To revolutionize cancer therapy by rapid identification and evaluation of biomarkers, this study set out to ascertain the frequency of cancer markers in Bangladesh’s north-central area. A cross-sectional investigation encompassing 463 individuals was conducted between March 2021 and July 2023. The detection of serum cancer biomarkers was accomplished by using an ELISA-based chemiluminescent microparticle immune assay. The independent variables were compared using an unpaired t-test. Five categories were created from the data clustering: Healthy control, group 1 (10-17 years, adolescent), group 2 (18 to 35 years, younger adult), group 3 (36 to 55 years, middle aged), and group 4 (>55 years, older adult). The serum level of PSA (prostate-specific antigen) was greater in group 4 compared to healthy control group (8.011 ± 1.281 ng/ml vs 1.307 ± 0.1598 ng/ml). The serum level of CA-125 (Carbohydrate Antigen-125) was greater in group 3 and group 4 compared to healthy control group (65.70 ± 6.430 vs 16.57 ± 0.793 and 1045 ± 275.8 vs 16.57 ± 0.793, respectively). The carcinoembryonic antigen (CEA) was expressed more often in group 4 male and female participants compared to the healthy controls (8.423 ± 0.5059 vs 2.436 ± 0.1086). Alpha-feto protein (AFP) was expressed more often in male group 3 and group 4 compared to healthy control group (15.24± 6.823 vs 4.615 ± 0.6613 and 18.54 ± 5.757 vs 4.615 ± 0.6613) and Male individuals reported a considerably greater amount of AFP than female individuals. This study revealed that older individuals had elevated levels of PSA, CA-125, CEA, and AFP. Moreover, males had greater levels of AFP than females.
References
Abbasi, A., Bhutto, A. R., Butt, N., & Munir, S. M. (2012). Correlation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc. 62(1):33-36.
Aune, D., Keum, N., & Giovannucci, E. (2016). Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. BMJ. 2016; 353: i2716. 10.1136/bmj.i2716
Campos-da-Paz, M., Dórea, J. G., Galdino, A. S., Lacava, Z. G. M., & de Fatima Menezes Almeida Santos, M. (2018). Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches. Recent Pat Biotechnol. 12(4):269-279. 10.2174/1872208312666180731104244
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F.O., Narod, S. A., & Akbari, M. R. (2020). CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 12(12):3730. doi:10.3390/cancers12123730
Einhorn, N., Sjövall, K., & Knapp R. C. (1992). Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 80(1):14-18.
Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., ... & Satpathy, M. (2017). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology, 3(4), 524-548.
Gobbi, P. G., Valentino, F., & Berardi, E. (2008). New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br J Cancer. 98(2):328-334. 10.1038/sj.bjc.6604114
Hanif, H., Ali, M. J., & Susheela, A. T. (2022). Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 28(2):216-229. doi:10.3748/wjg.v28.i2.216
Hasnat, M. A., Mia, M. W., Sarker, S., Chowdhury, M. B., Chowdhury, M. A., & Hasan, Z. (2022). Accessing the prevalence of cancer biomarkers in suspected patients from northeastern part of Bangladesh. J Adv Biotechnol Exp Ther. 6(1): 276-285.10.5455/jabet.2023.d125
Hussain, S. A., & Sullivan, R. (2013) Cancer control in Bangladesh. Jpn J Clin Oncol. 43:1159-69. 10.1093/jjco/hyt140
Hussein, S., Satturwar, S., & Van der Kwast, T. (2015). Young-age prostate cancer. J Clin Pathol. 68(7):511-515. 10.1136/jclinpath-2015-202993
Ilic, D., Djulbegovic, M., & Jung, J. H. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 362:k3519. doi:10.1136/bmj.k3519
Kamali, H., Golmohammadzadeh, S., Zare, H., Nosrati, R., Fereidouni, M., & Safarpour, H. (2022). The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors. J Nanobiotechnology. 20(1):438. doi:10.1186/s12951-022-01640-1
Knychalski, B., & Lukieńczuk, T. (2012). The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer. Pol Przegl Chir. 84(2):86-92. 10.2478/v10035-012-0014-3
Liu, X.Y., Jin, C., & Zhou, Y. (2022). High Prevalence of Abnormal Carcinoembryonic Antigen in Diabetic Inpatients with Poor Glycemic Control. Diabetes Metab Syndr Obes. 15:2345-2352. 10.2147/DMSO.S376024.
Mattiuzzi, C., & Lippi, G. (2019). Current Cancer Epidemiology. J Epidemiol Glob Health. 9(4):217-222. doi: 10.2991/jegh.k.191008.001
McGlynn, K. A., Petrick, J. L., & London, W. T. (2015). Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 19(2):223-238. 10.1016/j.cld.2015.01.001
Mittal, A., Sathian, B., Chandrashekharan, N., Farooqui, S. M., & Hussain, A. (2011). Diagnostic significance of alpha fetoprotein in carcinomas of liver and biliary tract - a comparative study from the western region of Nepal. Asian Pac J Cancer Prev. 12(12): 3475-3478.
Safi, F., Kohler, I., Röttinger, E., and Beger, H. (1991). The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer. 68(3):574-582. 10.1002/1097-0142(19910801)68:3<574::aid-cncr2820680322>3.0.co;2-b
Sarhadi, V. K., & Armengol, G. (2022). Molecular Biomarkers in Cancer. Biomolecules. 23; 12(8): 1021. doi: 10.3390/biom12081021. PMID: 35892331; PMCID: PMC9331210.
Sung, H., Ferlay, J., & Siegel, R. L. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209-249. doi:10.3322/caac.21660
Zhang, J., Chen, G., & Zhang, P. (2020). The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 15(2): e 0228857. 10.1371/journal.pone.0228857
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Aar Rafi Mahmud, Md. Monsur Ahammed, Majharul Islam, Fahim Alam Nobel, Mohammad Kamruzzaman, Mohammad Nasir Uddin, Mohammod Johirul Islam (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
